Balloon Dilation for Bladder Neck Contracture
Balloon dilation treats selected nonobliterative posterior stenoses. It is used as a standalone treatment and as the first step before incision or resection. In a 1994 post-prostatectomy series, 16/27 men (59%) responded to standalone fluoroscopic balloon dilation.[2] In a separate retrospective series, balloon dilation followed by incision produced patent outlets in 101/123 (82.1%) after one procedure and 116/123 (94.3%) after two; office cystoscopy was performed approximately 2 months after treatment, and median overall follow-up was 12 months.[2][3] Bladder-neck stenosis after benign prostate surgery and VUAS after radical prostatectomy should be distinguished. The EAU guideline recommends visually controlled dilation or direct vision internal urethrotomy as first-line treatment of nonobliterative VUAS and resection or hot-knife incision as first-line treatment of bladder-neck stenosis after benign outlet surgery . It recommends against endoluminal treatment of complete posterior obliteration .[1]
See TUIBNC, TURBN, BNC, and the drug-coated balloon evidence page.
Technique and selection
Define the stenosis, prior treatment, radiation injury and baseline continence. Establish the true lumen under vision, and use a guidewire and imaging as needed for safe positioning. Select the balloon and inflation parameters for the device and anatomy. Do not force access through an uncertain lumen. Dilation can injure the sphincter or create a false passage.[1]
Dilation can be repeated in selected nonobliterative recurrence after discussion of durability and alternatives. Increasing obstruction, recurrent procedures, fistula or tissue necrosis should prompt reassessment rather than further dilation.[1]
Standalone balloon dilation
Ramchandani evaluated fluoroscopically guided transurethral balloon dilation for VUAS after radical retropubic prostatectomy in a series of 45 consecutive patients. Balloon dilation was the primary treatment in 27, and 16 (59%) responded.[2] Ten of the 11 who did not respond underwent bladder-neck incision, and 7 of those 10 needed repeat attempts or subsequent balloon dilation. New incontinence developed in one patient treated primarily with incision and in none treated with balloon dilation. The authors suggested that refractoriness may relate to dense scar.[2] A 2024 meta-analysis of eight first-treatment VUAS dilation series, including balloons and graduated dilators, estimated 52.2% success at variable follow-up (95% CI 16.2%–86.1%; I² = 79%).[12] Success often meant no repeat procedure.[12]
The EAU guideline summarizes dilation series for VUAS and radiation-induced bulbomembranous stenosis as patency rates between 0% and 89%, a risk of de novo incontinence of 0% to 11% and no other reported complications (level of evidence 3).[1] Most series report visually controlled dilation in stenosis without complete obliteration.[1] The AUA guideline states that first-time VUAS is treated successfully in about 50% to 80% of cases and that endoscopic techniques have similar success rates; separately, it states that no studies directly compare strategies for bladder-neck contracture after endoscopic prostate procedures.[9] It lists dilation, vesicourethral incision and transurethral resection as options for post-prostatectomy VUAS and dilation, incision or resection for bladder-neck contracture after endoscopic prostate procedures .[9]
Balloon dilation as a preparatory step
Dilation of the contracture to admit the resectoscope, followed by deep incision or resection, is a common combined approach.
| Combined approach | Series | Outcome |
|---|---|---|
| 24 Fr balloon, then bilateral Collins-knife incisions at 3 and 9 o'clock (Nealon 2022) | 123 patients, retrospective; success defined as a patent bladder neck and 16 Fr cystoscope passage at office cystoscopy approximately 2 months after treatment; median overall follow-up 12 months | 101/123 (82.1%) patent after one procedure and 116/123 (94.3%) after a second. Two or more prior endoscopic procedures were associated with failure.[3] |
| Transurethral columnar balloon dilation of the prostate, then holmium laser incision, in a day-surgery model (Sun 2023) | 41 patients, retrospective | All completed within 24 h. Six patients had urge incontinence and one had recurrence at 12 months. IPSS, Qmax, quality of life and PVR were better at 1 and 6 months[7] |
These cohorts differ in selection, era, intervention and outcome definition. For the TUIBNC technique including the dilation step, see TUIBNC.
Drug-coated balloons in posterior stenosis
Treatment of posterior BNC or VUAS with a paclitaxel-coated balloon is off-label. The EAU 2026 panel finds evidence for these posterior uses too limited for a recommendation and advises collecting outcomes in a clinical trial or registry.[1] Current guideline-supported selection for anterior disease is narrower than all urethral stenoses; see the device pharmacology hub for labeling and paclitaxel precautions.[1]
Berg's retrospective comparative study included 65 DCB and 76 standard-treatment patients with posterior stenosis (VUAS and bladder-neck contracture), matched for age, initial treatment and radiotherapy history. DCB treatment was associated with better recurrence-free survival (log-rank p = 0.013).[4] The adjusted HR was 0.40 (95% CI 0.19–0.87), a 60% lower estimated hazard.[4] In the DCB group PVR fell from 55 mL to 0 mL and Qmax rose from 9 to 22 mL/s.[4] In a separate retrospective cohort of 59 posterior stenoses, 1-year Kaplan–Meier recurrence-free estimates were 75.8% for symptomatic recurrence requiring retreatment and 59.4% for cystoscopic anatomic recurrence; median follow-up for the overall 319-patient cohort was 5.7 months.[11] Different endpoints and short follow-up limit comparison with Berg.[11][4]
A 2025 narrative review reports success rates of 40% to 72% for traditional endoscopic treatment of posterior urethral stenosis, with 90% of patients needing repeat intervention within 2 years, and short-term success approaching 85% to 90% for newer endoscopic techniques including drug-coated balloon dilation and transurethral mucosal realignment. These are pooled descriptions of heterogeneous short-term series.[8]
In an international survey of 102 Optilume users, 61 of 94 respondents to the off-label-use item (65%) selected bladder-neck stenosis as an indication for which they would offer the device. Survey respondents performing 10 or more DCB procedures a year were more likely to offer it for bladder-neck stricture (OR 4.66, 95% CI 1.55–14.03).[5]
A dedicated retrospective outcomes series from two German centers followed 16 patients with recurrent bladder-neck stenosis or VUAS after prostate surgery (open or robotic radical prostatectomy, TURP or GreenLight PVP), all previously treated, who received off-label Optilume. At 12 months, all 16 remained free of repeat intervention and of anatomic recurrence, defined as symptomatic or retreatment-requiring narrowing on imaging or endoscopy; IPSS and IPSS quality-of-life scores improved significantly (each p < 0.001), and continence was stable with no worsening, including in the 7 patients with pre-existing incontinence. This is a small, single-arm series distinct from the comparative Berg study above.[10]
Before off-label posterior DCB use, check the current IFU (reference 6 is the FDA-hosted approval-time IFU, 1111-003 Rev A): paclitaxel-related hypersensitivity and urologic implants such as an artificial urinary sphincter or penile implant are contraindications, and active UTI must resolve before treatment. Counsel men to abstain from sex or use a condom for 30 days; those with partners of childbearing potential should use highly effective contraception and avoid fathering a child for at least 6 months.[6] These precautions apply even when the anatomical use is off-label. The IFU warns that repeat Optilume treatment of the same stricture increases paclitaxel exposure, with associated risks still unknown.[6] Drug and label details remain in the pharmacology hub.[6]
Complications and counseling
Discuss recurrence, bleeding, infection, extravasation and new or worsened incontinence. In the EAU summary for nontraumatic posterior stenosis, endoluminal treatment may be associated with de novo incontinence in up to 25% and worsening of existing incontinence in up to 15%.[1] Radiation injury and the need for subsequent continence surgery require particular planning. In a retrospective drug-coated-balloon series of 30 previously irradiated men, new stress incontinence developed in 3/15 who were continent before treatment at median 353-day follow-up.[13] Most lesions were membranous (21/30).[13] Refractory stenosis warrants specialist reconstructive assessment, and the choice depends on anatomy, bladder function and patient goals.[1]
References
1. European Association of Urology. EAU Guidelines on Urethral Strictures. 2026. Disease management in males, sections 6.3.5–6.3.6. Guideline.
2. Ramchandani P, Banner MP, Berlin JW, Dannenbaum MS, Wein AJ. Vesicourethral anastomotic strictures after radical prostatectomy: efficacy of transurethral balloon dilation. Radiology. 1994;193(2):345-9. doi:10.1148/radiology.193.2.7972741.
3. Nealon SW, Bhanvadia RR, Badkhshan S, et al. Transurethral incisions for bladder neck contracture: comparable results without intralesional injections. J Clin Med. 2022;11(15):4355. doi:10.3390/jcm11154355.
4. Berg EK, Mehmedovic S, Askari D, et al. Efficacy of drug-coated balloon dilation vs endoscopic standard treatment in posterior urethral stenosis: a real-world comparative study. Urology. 2025;206:164-170. doi:10.1016/j.urology.2025.07.034.
5. Sugrue DD, O'Connor J, Białek Ł, et al. Practices in urethral stricture management with drug-coated balloon dilatation: an international survey. World J Urol. 2026;44(1):285. doi:10.1007/s00345-026-06343-y.
6. Urotronic. Optilume Urethral Drug Coated Balloon: FDA-approved instructions for use. FDA labeling.
7. Sun J, Xia SQ, Tong Z, Xiao DD, Chen B. Transurethral columnar balloon dilation of the prostate combined with holmium laser incision for bladder neck contracture in day-surgery mode. Lasers Med Sci. 2023;38(1):279. doi:10.1007/s10103-023-03942-8.
8. Hudson CN, Damm T, Monn MF. Minimally invasive treatments for posterior urethral stenosis. J Endourol. 2025;39(10):1078-1084. doi:10.1177/08927790251371037.
9. Wessells H, Morey A, Souter L, Rahimi L, Vanni A. Urethral stricture disease guideline amendment (2023). J Urol. 2023;210(1):64-71. doi:10.1097/JU.0000000000003482.
10. Tosev G, Damgov I, Kuehhas F, Borgmann H, Struck J, Salem J, Kuru TH. Off-label Use of the Optilume Drug-coated Balloon in the Treatment of Bladder Neck Stenosis and Vesicourethral Anastomosis Stenosis. Eur Urol Open Sci. 2025;75:101-105. doi:10.1016/j.euros.2025.03.002.
11. Patel HV, Erickson BA, Abbasi B, et al. "Early Real-World Experience With Optilume Drug-coated Balloon for Anterior Urethral Strictures and Posterior Urethral Stenoses." Urology. 2026;207:233-238. doi:10.1016/j.urology.2025.10.025
12. Delchet O, Nourredine M, González Serrano A, et al. "Post-prostatectomy anastomotic stenosis: systematic review and meta-analysis of endoscopic treatment." BJU Int. 2024;133(3):237-245. doi:10.1111/bju.16141
13. Masopeh J, Garrigan A, Heinsimer K, Wiegand L. "Outcomes of drug-coated balloon dilation in patients with radiation-related urethral stenosis." Transl Androl Urol. 2025;14(8):2129-2134. doi:10.21037/tau-24-461